# v3.19  
  
## Related releases  
  
## Data changes  
  
Gene:  
ATP1A1 Gene Added  
FUS Gene Added  
HMGA1 Gene Added  
HMGA2 Gene Added  
HTATIP2 Gene Added  
INTS6 Gene Added  
TRIM27 Gene Added  
ZFP36L2 Gene Added  
  
Alteration:  
ALK F1174C, Mutation Effect Description Updated  
ALK F1174L, Mutation Effect Description Updated  
ALK F1245V, Mutation Effect Description Updated  
ALK G1128A, Mutation Effect Description Updated  
ALK CAD-ALK Fusion, Mutation Effect Description Updated  
ATP1A1 Gene Type Updated  
ATP1A1 L104R Added  
ATP1A1 V332G Added  
ATP1A1 G99R Added  
ATP1A1 L100_I104del Added  
ATP1A1 E960_A963delinsS Added  
ATP1A1 Amplification Added  
BRCA2 R2991H, Mutation Effect Description Updated  
BRCA2 P2639A, Mutation Effect Description Updated  
BRCA2 R2787H, Mutation Effect Description Updated  
BRCA2 E3071D, Mutation Effect Description Updated  
BRCA2 F2873C, Mutation Effect Description Updated  
BRCA2 L2929W, Mutation Effect Description Updated  
BRCA2 R2787C, Mutation Effect Description Updated  
BRCA2 S3123G, Mutation Effect Description Updated  
BRCA2 L2587F, Mutation Effect Description Updated  
BRCA2 R2494Q, Mutation Effect Description Updated  
BRCA2 R2488G, Mutation Effect Description Updated  
BRCA2 S2807L, Mutation Effect Description Updated  
BRCA2 L2768H, Mutation Effect Description Updated  
BRCA2 V3081A, Mutation Effect Description Updated  
BRCA2 R2488S, Mutation Effect Description Updated  
BRCA2 G2508S, Mutation Effect Description Updated  
BRCA2 S2522F, Mutation Effect Description Updated  
BRCA2 Y3035S, Oncogenicity Updated  
	 New: Likely Neutral  
	 Old: Inconclusive  
BRCA2 G2584D, Oncogenicity Updated  
BRCA2 L2972W, Oncogenicity Updated  
BRCA2 L3011P, Oncogenicity Updated  
BRCA2 L2654P, Oncogenicity Updated  
	 New: Likely  
CDK12 E928_L929insYTKI Added  
EGFR V786M Added  
EGFR HMGA2-EGFR Fusion Added  
EGFR S492R, Mutation Effect Updated  
	 New: Likely Gain-of-function  
EGFR L718Q, Oncogenicity Updated  
	 New: Resistance  
	 Old: Likely  
EGFR L844V, Oncogenicity Updated  
EGFR L833F, Oncogenicity Updated  
	 New: Inconclusive  
EGFR A755G, Oncogenicity Updated  
ERBB2 D277Y, Oncogenicity Updated  
	 New: Yes  
FUS Gene Type Updated  
FUS Amplification Added  
FUS FUS-CHOP Fusion Added  
FUS FUS-ERG Fusion Added  
FUS FUS-CREB3L2 Fusion Added  
HMGA1 Gene Type Updated  
HMGA1 Amplification Added  
HMGA1 TBL1XR1-HMGA1 Fusion Added  
HMGA2 Gene Type Updated  
HMGA2 Amplification Added  
HMGA2 HMGA2-LPP Fusion Added  
HTATIP2 Gene Type Updated  
HTATIP2 Truncating Mutations Added  
HTATIP2 Deletion Added  
INTS6 Gene Type Updated  
INTS6 Deletion Added  
INTS6 Deletion, Mutation Effect Description Updated  
RET TRIM27-RET Fusion Added  
ROS1 G2032R, Mutation Effect Description Updated  
ROS1 S1986F, Mutation Effect Description Updated  
TP53 P151H, Mutation Effect Description Updated  
TP53 P151A, Mutation Effect Updated  
	 New: Likely Loss-of-function  
	 Old: Loss-of-function  
TP53 Y236C, Mutation Effect Updated  
TP53 Y236D, Mutation Effect Updated  
TP53 Y236S, Mutation Effect Updated  
TP53 P278S, Mutation Effect Description Updated  
TP53 P278L, Mutation Effect Updated  
TP53 P278A, Mutation Effect Description Updated  
TP53 P278R, Mutation Effect Updated  
TP53 C135R, Mutation Effect Description Updated  
TP53 C135S, Mutation Effect Description Updated  
TP53 C275S, Mutation Effect Description Updated  
TP53 M237K, Mutation Effect Description Updated  
TP53 S241F, Mutation Effect Description Updated  
TP53 S241T, Mutation Effect Updated  
TP53 V272M, Mutation Effect Description Updated  
TP53 V272L, Mutation Effect Updated  
	 Old: Likely Loss-of-function  
TP53 V157F, Mutation Effect Description Updated  
TP53 V157D, Mutation Effect Description Updated  
TP53 R280K, Mutation Effect Description Updated  
TP53 R280T, Mutation Effect Description Updated  
TRIM27 Gene Type Updated  
TRIM27 Amplification Added  
ZFP36L2 Gene Type Updated  
ZFP36L2 Deletion Added  
ZFP36L2 Truncating Mutations Added  
ZFP36L2 Amplification Added  
ZFP36L2 G145fs* Added  
Evidence:  
ALK Oncogenic Mutations, Non-Small Cell Lung Cancer, Lorlatinib  Updated  
BRAF V600E, V600K, Melanoma, Encorafenib + Binimetinib  Updated  
BRCA1 Oncogenic Mutations, Ovarian Cancer, Ovary/Fallopian Tube, Peritoneal Serous Carcinoma, Olaparib, Olaparib + Bevacizumab  Updated  
BRCA1 Oncogenic Mutations, Ovarian Cancer, Ovary/Fallopian Tube, Peritoneal Serous Carcinoma, Rucaparib 2 Updated  
BRCA1 Oncogenic Mutations, Ovarian Cancer, Ovary/Fallopian Tube, Peritoneal Serous Carcinoma, Niraparib 2 Updated  
BRCA1 Oncogenic Mutations, Ovarian Cancer, Ovary/Fallopian Tube, Peritoneal Serous Carcinoma, Tumor Type Summary Updated  
BRCA1 Oncogenic Mutations, Ovarian Cancer, Ovary/Fallopian Tube, Peritoneal Serous Carcinoma, Niraparib  Updated  
BRCA1 Oncogenic Mutations, Ovarian Cancer, Ovary/Fallopian Tube, Peritoneal Serous Carcinoma, Rucaparib  Updated  
BRCA1 Oncogenic Mutations, Ovarian Cancer, Ovary/Fallopian Tube, Peritoneal Serous Carcinoma, Niraparib 1 Updated  
BRCA1 Oncogenic Mutations, Ovarian Cancer, Ovary/Fallopian Tube, Peritoneal Serous Carcinoma, Rucaparib 1 Updated  
BRCA2 Oncogenic Mutations, Ovarian Cancer, Ovary/Fallopian Tube, Peritoneal Serous Carcinoma, Niraparib 2 Updated  
BRCA2 Oncogenic Mutations, Ovarian Cancer, Ovary/Fallopian Tube, Peritoneal Serous Carcinoma, Rucaparib 2 Updated  
BRCA2 Oncogenic Mutations, Ovarian Cancer, Ovary/Fallopian Tube, Peritoneal Serous Carcinoma, Tumor Type Summary Updated  
BRCA2 Oncogenic Mutations, Ovarian Cancer, Ovary/Fallopian Tube, Peritoneal Serous Carcinoma, Rucaparib 1 Updated  
BRCA2 Oncogenic Mutations, Ovarian Cancer, Ovary/Fallopian Tube, Peritoneal Serous Carcinoma, Niraparib 1 Updated  
FLT3 572_630ins [Internal tandem duplication], Acute Myeloid Leukemia, Quizartinib  Updated  
IDH1 R132C, R132H, R132G, R132S, R132L, Acute Myeloid Leukemia, Olutasidenib 1 Added  
IDH1 R132C, R132H, R132G, R132S, R132L, Acute Myeloid Leukemia, Tumor Type Summary Updated  
IDH1 Oncogenic Mutations, Other Tumor Types, Tumor Type Summary Updated  
KRAS G12C, Colorectal Cancer, Adagrasib, Adagrasib + Cetuximab  Updated  
Other Biomarkers MSI-H [Microsatellite Instability-High], Colorectal Cancer, Nivolumab  Updated  
Other Biomarkers MSI-H [Microsatellite Instability-High], Colorectal Cancer, Ipilimumab + Nivolumab  Updated  
